9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Sei Investments Co.

Sei Investments Co. acquired a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 9,378 shares of the company's stock, valued at approximately $502,000.

Other large investors have also recently modified their holdings of the company. Rhumbline Advisers lifted its position in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after buying an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 10.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after buying an additional 1,095 shares in the last quarter. Virtu Financial LLC increased its holdings in shares of Janux Therapeutics by 17.5% in the fourth quarter. Virtu Financial LLC now owns 8,769 shares of the company's stock worth $469,000 after purchasing an additional 1,306 shares during the period. Avanza Fonder AB purchased a new position in shares of Janux Therapeutics during the fourth quarter worth about $139,000. Finally, Chicago Capital LLC bought a new stake in shares of Janux Therapeutics during the 4th quarter worth $230,000. Institutional investors own 75.39% of the company's stock.

Insiders Place Their Bets

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now owns 82,139 shares of the company's stock, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the purchase, the director now directly owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. 29.40% of the stock is owned by insiders.

Remove Ads

Janux Therapeutics Price Performance

JANX stock traded up $0.04 during mid-day trading on Tuesday, reaching $28.99. 68,455 shares of the company's stock were exchanged, compared to its average volume of 852,656. Janux Therapeutics, Inc. has a 12-month low of $22.52 and a 12-month high of $71.71. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -24.74 and a beta of 3.27. The stock's 50 day moving average is $31.41 and its 200 day moving average is $44.02.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JANX has been the topic of a number of research analyst reports. Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Wedbush reiterated an "outperform" rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $92.44.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.